Nuclear medicine, made clear.
nucmed.net is an online platform dedicated to nuclear medicine education. The ultimate goal is to create a dynamic, comprehensive and interactive resource of molecular imaging and theranostics.
Cases →
Large vessel vasculitis
by Nazim Coskun
Septic embolism (infective endocarditis)
by Nazim Coskun
Transthyretin cardiac amyloidosis
by Nazim Coskun
Male breast cancer (FDG)
by Nazim Coskun
Squamous cell carcinoma of the lung
by Nazim Coskun
Desmoid tumor
by Nazim Coskun
Splenic hemangioma
by Nazim Coskun
Sinonasal melanoma
by Nazim Coskun
Recent Bookmarks →
A hand-crafted list of notable publications and news in the field of nuclear medicine and theranostics.
Transarterial Radioembolization Can Downstage Intermediate and Advanced Hepatocellular Carcinoma to Liver Transplantation
TARE allows for a 44% chance of response, 30% downstaging, and 23% probability of permitting liver transplantation in intermediate and advanced HCC.
journals.lww.comEvaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary
18F-FDG PET/CT plays a complementary role in CUP diagnostic work-up and was able to determine the likely primary site in 41% of cases. OS is improved with primary site identification, demonstrating the value of access to diagnostic 18F-FDG PET/CT for CUP patients.
jnm.snmjournals.orgThe LUTADOSE trial: tumour dosimetry after the first administration predicts PFS in GEP NET patients treated with 177Lu-DOTATATE
Patients with a mean tumour absorbed dose lower than the best cut-off value of 10.6 Gy after first cycle had a significantly shorter median PFS (HR 8.6, 95% CI: 2–37).
link.springer.comPrognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer
Salvage RT is associated with delayed clinical progression in patients with post radical prostatectomy biochemical recurrence and negative PSMA PET/CT (HR: 0.2, p=0.03). Median follow-up was 39 months.
pubmed.ncbi.nlm.nih.gov
Clinical Trials →
Comparing Retreatment of 177Lu-DOTATATE PRRT versus Everolimus in Patients with Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Phase 2 • Updated on Oct 8, 2024
Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Phase 1 • Updated on Oct 8, 2024
Radium-223 in Biochemically Recurrent Prostate Cancer
Phase 2 • Updated on Oct 8, 2024
Upcoming Events →
BNMS Autumn Meeting 2024
Oct 14-15, Norwich, UKEANM 2024
Oct 19-23, Hamburg, GermanyFocus on Molecular-guided Surgery
Nov 14-15, Barcelona, SpainTreatment of Metastatic Bone Pain Using Bone-Seeking Agents (MSK)
Dec 6, Live WebinarAlgorithms for Dementia Imaging
Dec 12-13, Vienna, Austria